Biomed Industries
Biomed Industries, Inc. is a bio-pharmaceutical company focused on developing and commercializing novel drug therapeutics for unmet medical needs in neurological, metabolic, and cardiovascular diseases. They leverage AI and Machine Learning for drug discovery and development. Their pipeline includes treatments for ALS (NA-704), Alzheimer's disease (NA-831), major depressive disorder (NA-901), stroke (NA-911), diabetes/obesity (NA-931), liver diseases MASH (NA-941), and rare diseases like Rett Syndrome (NA-921). Their Unified Acceleration Platform is based on Dr. Lloyd Tran's Unified Theory, positing shared dysfunctions across these disease categories. NA-931 (Bioglutide) is an oral quadruple receptor agonist for obesity, demonstrating efficacy comparable to injectables with fewer side effects. NA-831 is an oral drug for Alzheimer's that promotes neurogenesis. Biomed aims to provide safe, effective, and accessible oral therapies.
Biomed Industries
Biomed Industries, Inc. is a bio-pharmaceutical company focused on developing and commercializing novel drug therapeutics for unmet medical needs in neurological, metabolic, and cardiovascular diseases. They leverage AI and Machine Learning for drug discovery and development. Their pipeline includes treatments for ALS (NA-704), Alzheimer's disease (NA-831), major depressive disorder (NA-901), stroke (NA-911), diabetes/obesity (NA-931), liver diseases MASH (NA-941), and rare diseases like Rett Syndrome (NA-921). Their Unified Acceleration Platform is based on Dr. Lloyd Tran's Unified Theory, positing shared dysfunctions across these disease categories. NA-931 (Bioglutide) is an oral quadruple receptor agonist for obesity, demonstrating efficacy comparable to injectables with fewer side effects. NA-831 is an oral drug for Alzheimer's that promotes neurogenesis. Biomed aims to provide safe, effective, and accessible oral therapies.